Additional file 4 of The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
posted on 2020-02-26, 04:42authored byMichael Bretscher, Prabin Dahal, Jamie Griffin, Kasia Stepniewska, Quique Bassat, Elisabeth Baudin, Umberto D’Alessandro, Abdoulaye Djimde, Grant Dorsey, Emmanuelle Espié, Bakary Fofana, Raquel González, Elizabeth Juma, Corine Karema, Estrella Lasry, Bertrand Lell, Nines Lima, Clara Menéndez, Ghyslain Mombo-Ngoma, Clarissa Moreira, Frederic Nikiema, Jean Ouédraogo, Sarah Staedke, Halidou Tinto, Innocent Valea, Adoke Yeka, Azra Ghani, Philippe Guerin, Lucy Okell
Additional file 4: Figure S3. Sensitivity analysis of PCR-correction misclassification: time to reinfection after treatment and model fits. Here we repeated the analysis shown in Fig. 2 of the main text on a modified dataset, in which we explored the impact of reclassifying some reinfections as recrudescences and removing them from the analysis. To reclassify reinfections for each trial arm, we sampled a number of reinfections equal to 3% of the study population, with probability weighted according to the estimated timings of recrudescence in Fig. 5 of [66] and the relative frequency of apparent ‘reinfection’ timing in the current dataset (such that the probabilities of sampling of reinfections, if present, at days 7,14,21,28,35, and 42 were 0.799, 0.100, 0.026, 0.014, 0.049, and 0.012). One site, Ndola in Zambia, was excluded after reclassification of reinfections, since one trial arm no longer contained reinfections and the model could not be fitted. The Figure shows the proportion of patients reinfected during follow up, amongst patients not experiencing recrudescence, after treatment at day 0 with AL (blue) or AS-AQ (green) in each of the 11 trial sites included in this sensitivity analysis. Circles show data with 95% CI, and the lines are the fits of the hidden semi-Markov model in each site. Here, the AL trial arms include in total 1956 individuals, 573 reinfections, and the AS-AQ trial arms, 2001 individuals, 475 reinfections.